What's Happening?
Amgen, a biotechnology company, is actively recruiting for a Value & Access Senior Manager, 340B Analytics. This U.S. remote position is central to leading forecasting, financial modeling, and data analytics for Amgen’s 340B Drug Pricing program. The
role involves translating complex claims, payment, and policy information into brand-level forecasts, scenario analyses, and recommendations to support financial planning and business decisions. The Senior Manager will collaborate with various internal departments, including Finance, Policy, Legal, Operations, and Coverage & Pricing, to guide program strategy and execution as the external environment evolves. Key responsibilities include developing and refining brand-level 340B forecasts, building scenario and sensitivity analyses, monitoring for anomalies and claim variances, and analyzing detailed claims data to identify trends and produce actionable insights. The company emphasizes its mission to serve patients living with serious illnesses by advancing a broad pipeline of medicines for conditions such as cancer, heart disease, inflammatory conditions, rare diseases, and obesity. Amgen has been a pioneer in biotech since 1980, focusing on Oncology, Inflammation, General Medicine, and Rare Disease therapeutic areas.
Why It's Important?
This recruitment highlights Amgen's strategic focus on optimizing its 340B Drug Pricing program, which is crucial for managing drug costs and ensuring patient access to essential medicines. The 340B program allows eligible healthcare organizations to purchase outpatient drugs at discounted prices, and effective management of this program can significantly impact a pharmaceutical company's financial performance and its ability to serve a broader patient population. By investing in a senior analytical role, Amgen aims to enhance its financial modeling and forecasting capabilities, which are vital for navigating the complex landscape of drug pricing and policy. This move could lead to more efficient resource allocation, better compliance, and improved financial outcomes for Amgen, ultimately benefiting its stakeholders and patients by potentially making treatments more accessible. The role's emphasis on understanding policy changes also underscores the dynamic regulatory environment in the U.S. healthcare sector, where policy shifts can have profound effects on drug manufacturers and healthcare providers.
What's Next?
The successful candidate for the Value & Access Senior Manager, 340B Analytics position will be instrumental in shaping Amgen's strategy for its 340B program. This will involve continuous monitoring of 340B news and policy changes, developing analytical capabilities to support evolving strategies, and ensuring data integrity and compliance across claims and payment systems. The role will also involve partnering with finance and other cross-functional stakeholders to align model assumptions and translate analyses into operational decisions. This strategic hire suggests Amgen's commitment to adapting to the evolving healthcare landscape and maintaining a competitive edge in drug pricing and market access. The ongoing refinement of forecasting and financial models will likely lead to more informed business decisions and potentially influence Amgen's pricing strategies and patient access initiatives in the coming years. The company's continued focus on its core therapeutic areas, supported by robust analytics, indicates a sustained effort to deliver innovative medicines to patients.
Beyond the Headlines
The creation of this specialized role within Amgen reflects a broader trend in the pharmaceutical industry towards increased sophistication in managing complex drug pricing programs like 340B. The 340B program itself has been a subject of ongoing debate and scrutiny, with discussions around its scope, oversight, and impact on drug manufacturers and healthcare providers. By strengthening its internal analytics capabilities, Amgen is not only aiming for operational efficiency but also positioning itself to better respond to potential regulatory changes or challenges to the 340B program. This strategic investment in data-driven decision-making underscores the growing importance of analytics in navigating the intricate ethical and economic dimensions of drug pricing, ensuring both business sustainability and patient welfare. The role's focus on identifying anomalies and ensuring compliance also highlights the industry's commitment to ethical practices and transparency in drug distribution and pricing.













